menu
    • menu
    [{"orgOrder":0,"company":"Neumirna Therapeutics","sponsor":"Angelini Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Oligonucleotide","year":"2025","type":"Series A Financing","leadProduct":"NMT.001","moa":"miR-134","graph1":"Neurology","graph2":"Preclinical","graph3":"Neumirna Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Neumirna Therapeutics \/ Angelini Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Neumirna Therapeutics \/ Angelini Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals by Neumirna Therapeutics

    Menu

    Neumirna Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neumirna Therapeutics

                            Denmark arrow
                            AAPS
                            Not Confirmed

                            Neumirna Therapeutics

                            Denmark arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NMT.001

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Angelini Ventures

                            Deal Size : $20.9 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Angelini, Neumirna Lead €20M Series A for RNA Therapy in Neurological Disorders

                            Details : The proceeds from the financing will enable Neumirna to advance its lead asset NMT.001 for the treatment of epilepsy.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : NMT.001

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Angelini Ventures

                            Deal Size : $20.9 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth